Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Keating

Showing results (761-770 of 1,115) with videos related to

Pageof 112
Sort By:
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|March 20, 2009
NKCC1-dependent GABAergic excitation drives synaptic network maturation during early hippocampal developmentCarsten K Pfeffer, Valentin Stein, Damien J Keating, et al.
Cancer|November 21, 2015
β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemiaPhilip A Thompson, Susan M O'Brien, Lianchun Xiao, et al.
Cancer|August 15, 1988
Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemiaR S Walters, H M Kantarjian, M J Keating, et al.
Haematologica|July 7, 2018
Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathwaysLynne V Abruzzo, Carmen D Herling, George A Calin, et al.
Blood|January 10, 2009
The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease courseConstantine S Tam, Lynne V Abruzzo, Katherine I Lin, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 2, 2013
Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndromeApostolia M Tsimberidou, William G Wierda, Sijin Wen, et al.
Human Genetics|March 7, 2016
Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic riskVinicius Tragante, Folkert W Asselbergs, Daniel I Swerdlow, et al.
British Journal of Haematology|May 15, 2008
MYC translocation in chronic lymphocytic leukaemia is associated with increased prolymphocytes and a poor prognosisYang O Huh, Katherine I-Chun Lin, Francisco Vega, et al.
Clinical Genetics|February 24, 2015
Utility of next-generation sequencing technologies for the efficient genetic resolution of haematological disordersJ Zhang, P Barbaro, Y Guo, et al.
Cancer|April 2, 2011
Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcomeIssa F Khouri, Roland Bassett, Nancy Poindexter, et al.
Pageof 112

Showing results (761-770 of 1,115) with videos related to

Sort By:
Pageof 112
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|March 20, 2009
NKCC1-dependent GABAergic excitation drives synaptic network maturation during early hippocampal developmentCarsten K Pfeffer, Valentin Stein, Damien J Keating, et al.
Cancer|November 21, 2015
β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemiaPhilip A Thompson, Susan M O'Brien, Lianchun Xiao, et al.
Cancer|August 15, 1988
Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemiaR S Walters, H M Kantarjian, M J Keating, et al.
Haematologica|July 7, 2018
Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathwaysLynne V Abruzzo, Carmen D Herling, George A Calin, et al.
Blood|January 10, 2009
The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease courseConstantine S Tam, Lynne V Abruzzo, Katherine I Lin, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 2, 2013
Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndromeApostolia M Tsimberidou, William G Wierda, Sijin Wen, et al.
Human Genetics|March 7, 2016
Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic riskVinicius Tragante, Folkert W Asselbergs, Daniel I Swerdlow, et al.
British Journal of Haematology|May 15, 2008
MYC translocation in chronic lymphocytic leukaemia is associated with increased prolymphocytes and a poor prognosisYang O Huh, Katherine I-Chun Lin, Francisco Vega, et al.
Clinical Genetics|February 24, 2015
Utility of next-generation sequencing technologies for the efficient genetic resolution of haematological disordersJ Zhang, P Barbaro, Y Guo, et al.
Cancer|April 2, 2011
Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcomeIssa F Khouri, Roland Bassett, Nancy Poindexter, et al.
Pageof 112